China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its clinical study for the oral small molecule COVID-19 therapy GS221, a 3CLpro inhibitor, has delivered a good safety and tolerability profile. The study, approved in late September, observed no serious adverse events or adverse events leading to discontinuation.
Efficacy Study of GS221
An ongoing study assessing the efficacy of GS221 in mild to moderate COVID-19 consists of two phases. The first phase enrolled 70 asymptomatic/mild/ordinary patients with positive COVID-19 nucleic acid test, while the second phase enrolled 312 mild/ordinary patients with positive COVID-19 nucleic acid test. Both phases were randomized, double-blinded, and placebo-controlled to explore the time of nucleic acid negative conversion, improvement of related symptoms, and drug safety. The first phase has completed enrollment and follow-up of all patients, showing good safety with no serious adverse events or adverse events leading to drug withdrawal. Patients showed a trend of improving clinical symptoms, shortening the time for nucleic acid to turn negative, and rapidly decreasing the viral load, suggesting potential clinical benefits for patients. The second phase has been initiated, and subject enrollment is underway.
Sepsis Drug STC3141 Progress
In the meantime, Grand Pharma’s innovative sepsis drug STC3141 has concluded a Phase IIa study in COVID-19-induced severe pneumonia, having reached its primary endpoint. A study for the drug in China is well underway, highlighting Grand Pharma’s commitment to advancing innovative therapies for critical conditions.-Fineline Info & Tech
